Core Viewpoint - The stock of Yaojie Ankang (2617.HK) experienced extreme volatility, reaching a peak of 679.5 HKD per share before plummeting by 53.73% to close at 192 HKD, resulting in a market capitalization loss of nearly 200 billion HKD [1][3]. Company Overview - Yaojie Ankang, founded in 2014, is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [4]. - The company completed nine rounds of financing before its IPO, raising approximately 1.723 billion HKD from over twenty institutions, with a valuation increase from 263 million HKD to 4.59 billion HKD prior to listing [4]. Stock Performance - The stock was listed on the Hong Kong Stock Exchange on June 23, 2023, with an initial price of 13.15 HKD per share, achieving a 50-fold increase in less than three months [3]. - Following its inclusion in the Hong Kong Stock Connect on September 8, 2023, the stock surged over 200% in the subsequent seven trading days [3]. Product Pipeline - The core product, Tinengotinib, is a multi-target kinase inhibitor aimed at key pathways including FGFR/VEGFR, JAK, and Aurora, with no direct competitors in development globally [5]. - On September 10, 2023, the company announced that it received clinical approval for a Phase II trial of Tinengotinib in combination with Fulvestrant for treating hormone receptor-positive, HER2-negative metastatic breast cancer [6]. Financial Performance - Yaojie Ankang has not yet commercialized any products and is currently operating at a loss, with projected pre-tax losses of 252 million HKD, 343 million HKD, and 275 million HKD for the years 2022, 2023, and 2024, respectively, totaling 870 million HKD [6]. Major Shareholders - The chairman and actual controller, Wu Yongqian, has over 27 years of experience in the pharmaceutical industry and holds 12.06% of the company's shares, with a total voting power of 34.29% [8]. - As of June 2023, Wu's personal stake was valued at approximately 9.2 billion HKD based on the closing price on September 16, 2023 [8].

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced extreme volatility today, with a peak increase of over 60% in the morning, followed by a sharp decline of more than 60% in the afternoon, leading to significant market capitalization loss. Group 1: Stock Performance - In the morning, the stock price reached a high of 679.5 HKD per share, with market capitalization nearing 270 billion HKD [1][2] - By the afternoon, the stock price plummeted to a low of 165 HKD per share, resulting in a drop of 60.24% [2] - The closing price was reported at 192 HKD per share, reflecting a decrease of 53.73% and a market capitalization of 76.2 billion HKD [2] Group 2: Company Announcements - The company issued a statement acknowledging the unusual stock price and trading volume fluctuations, stating that it was unaware of any reasons for these changes [4] - The board confirmed that there were no significant changes in the company's business operations or financial status [4] Group 3: Historical Context -药捷安康 was listed on the Hong Kong Stock Exchange on June 23, with an initial price of 13.15 HKD per share, and has seen its stock price increase significantly since then [5] - The stock price surged nearly 500% from September 10 to September 15, with a peak price of 679.5 HKD representing a 5067% increase from the initial listing price [6] Group 4: Financial Performance - The company remains in a loss position, with a pre-tax loss of 123 million HKD for the first half of the year, an improvement from a loss of 160 million HKD in the same period last year [6] - Other income and revenue decreased by 65.1%, from 10.4 million HKD to 3.6 million HKD, primarily due to reduced bank interest and government subsidies [6] - Research and development costs decreased by 30.9% to 98.43 million HKD, attributed to lower clinical trial expenses for the TT-00420 project [6]

Core Viewpoint - The stock of Hong Kong innovative pharmaceutical company, Yaojie Ankang, experienced significant volatility, soaring over 50% before plummeting to a closing price of 192 HKD after a series of announcements regarding its clinical trials and product developments [1][5]. Group 1: Stock Performance - Since September, Yaojie Ankang's stock price surged from around 60 HKD to over 600 HKD, drawing considerable market attention [2]. - The stock saw a notable increase following a September 4 announcement regarding the initiation of a clinical trial for its core product, Tinengotinib, which is aimed at treating advanced liver cancer [2]. - Following the announcement, the stock price rose by 5.43% on September 5, reaching 63.1 HKD, and continued to climb, hitting 90 HKD with a 27.57% increase on September 10 [2][3]. Group 2: Clinical Developments - Yaojie Ankang's core product, Tinengotinib, is a unique MTK inhibitor currently in the registration clinical stage, targeting several difficult-to-treat solid tumors [2]. - On September 10, the company announced the approval of a Phase II clinical trial for Tinengotinib in combination with Fulvestrant for treating HR+/HER2- breast cancer, which is expected to provide new treatment options for patients [3]. Group 3: Financial Performance - Despite the stock price surge, Yaojie Ankang reported zero revenue, with significant operating losses of 343 million RMB and 275 million RMB expected for 2023 and 2024, respectively, due to high R&D and management costs [4]. - As of mid-2023, the company had not generated any revenue, with a loss of 123 million RMB reported for the first half of the year [4].

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced extreme volatility today, with an initial surge of over 60% followed by a sharp decline, highlighting the unpredictable nature of the market and investor sentiment [1][2][4]. Group 1: Stock Price Movement - In the morning, the stock price peaked at 679.5 HKD per share, bringing the market capitalization close to 270 billion HKD [1][2]. - After an announcement regarding unusual trading activity, the stock price plummeted to a low of 165 HKD per share, resulting in a decline of over 60% [2][4]. - By the end of the trading day, the stock closed at 192 HKD per share, reflecting a decrease of 53.73% and a market capitalization of 76.2 billion HKD [2]. Group 2: Company Announcements - The company issued a statement confirming that it was unaware of the reasons behind the stock price and trading volume fluctuations, asserting that its business operations and financial status remained stable [4]. - The board of directors indicated that there were no significant changes in the company's operations or financial conditions that warranted disclosure [4]. Group 3: Recent Performance and Developments -药捷安康's stock has seen a dramatic increase since its listing on June 23, with a rise of over 500% from September 10 to September 15 [6]. - The company’s core product, Tinengotinib, received clinical trial approval for treating specific types of breast cancer, contributing to the stock's previous surge [5][6]. - Despite the stock's volatility, the company remains in a loss-making position, with a reported pre-tax loss of 123 million HKD for the first half of the year, an improvement from the previous year's loss of 160 million HKD [7].

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced significant volatility, dropping 45% after previously surging 63% to a peak of 679.5 HKD per share [1][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [3]. - The company has no commercialized products and reported zero revenue with a loss of 123 million HKD in the first half of the year [3]. Stock Performance - The stock price increased dramatically, with a cumulative rise of over 30 times since its IPO price of 13.15 HKD, reaching a market capitalization exceeding 120 billion HKD [3]. - The stock was recently included in the Hong Kong Stock Connect program, allowing southbound funds to invest in it [3]. Clinical Developments - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- metastatic breast cancer [3][4]. - Early clinical results indicated promising effects of Tinengotinib as a monotherapy in patients with HR+/HER2- breast cancer who have undergone multiple treatments [4]. Competitive Landscape - There are currently no other products in development with the same mechanism as Tinengotinib, although there are various competitors in related cancer treatment areas [7]. - The market for small molecule drugs is competitive, with larger biologics generally having greater potential [7]. Shareholding Structure - The founder, Wu Yongqian, holds a 32.98% stake in the company, contributing to a limited market float with only 15.281 million shares available for trading out of a total of 397 million shares [7]. - The stock exhibited a trading volatility of 131.09% with a low turnover rate of 4.74% as of September 12 [7]. Company History -药捷安康 has faced challenges in its journey to listing, having attempted to go public on three occasions in 2021, 2022, and 2024 [8]. - The company has a pipeline of six clinical-stage candidates and one preclinical candidate [8].

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced significant volatility, dropping 45% after a previous surge of 63%, highlighting the speculative nature of its recent trading activity [2][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases. The company currently has no commercialized products and reported zero revenue with a loss of 123 million yuan in the first half of the year [2]. Recent Developments - The company was recently added to the Hong Kong Stock Connect list, allowing southbound funds to purchase its shares [3]. - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- metastatic breast cancer [3]. Competitive Landscape - Industry experts noted that there are currently no other products in development with the same mechanism as Tinengotinib, although there are various competitors in related cancer treatment areas [6]. - Despite the innovative mechanism of Tinengotinib, the stock price increase has been described as excessive, and the potential of large molecule drugs is generally considered greater than that of small molecules [6]. Market Dynamics - The founder of药捷安康, Wu Yongqian, holds a 32.98% stake in the company, contributing to a limited market float. Out of a total of 397 million shares, only 15.28 million are available for trading in the secondary market [6]. - The stock exhibited a trading volatility of 131.09% with a turnover rate of only 4.74%, indicating a tight liquidity situation [6]. Historical Context -药捷安康 has faced a challenging path to listing, having attempted to go public on three occasions in 2021, 2022, and 2024 [7]. - The company has a pipeline of six clinical-stage candidates and one preclinical candidate [7].

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced a significant drop of 45% after previously soaring by 63% and reaching a peak of 679.5 HKD per share, indicating high volatility in the market [1][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases. The company has no commercialized products and reported zero revenue with a loss of 123 million HKD in the first half of the year [3][4]. - The company’s market capitalization exceeded 120 billion HKD, having increased over 30 times since its IPO price of 13.15 HKD less than three months ago [3]. Recent Developments - On September 10, the company received clinical trial approval from the National Medical Products Administration of China for its core product, Tinengotinib (TT-00420), in a Phase II trial for treating hormone receptor-positive, HER2-negative metastatic breast cancer [3][4]. - Early clinical results for Tinengotinib show promising effects in patients with HR+/HER2- breast cancer who have undergone multiple treatments, suggesting potential breakthroughs in treatment strategies [4]. Market Context - There are currently no other products in development with the same mechanism as Tinengotinib, although there are competing products in various cancer treatment areas [7]. - The stock's dramatic price fluctuations are attributed to limited market circulation, with only 15.28 million shares available for trading out of a total of 397 million shares [7][9].

Core Viewpoint - The stock price of the biopharmaceutical company,药捷安康-B (2617.HK), surged again today, reaching a peak increase of 63% to HKD 679.5, marking a five-day cumulative rise of 863% and setting a new record since its IPO, with a market capitalization nearing HKD 270 billion [1] Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - The company currently has no commercialized products and reported zero revenue with a loss of HKD 123 million in the first half of this year [1] Clinical Development - On September 10, the company announced that its core product,替恩戈替尼 (TT-00420), in combination with fluorouracil, received implied approval from the National Medical Products Administration of China for a Phase II clinical trial targeting HR+/HER2- recurrent or metastatic breast cancer, expected to conclude by September 10, 2025 [1] - The trial is an open-label, multi-center study aimed at evaluating the safety, efficacy, and pharmacokinetics of the combination therapy [1]

Core Viewpoint - The stock of药捷安康-B (02617) has surged over 60% in early trading, reaching a high of 679.5 HKD, with a cumulative increase of nearly 10 times since its inclusion in the Hong Kong Stock Connect program [1] Group 1: Stock Performance - As of the latest update, the stock is up 50.6%, trading at 625.5 HKD, with a transaction volume of 1.177 billion HKD and a market capitalization that briefly exceeded 250 billion HKD [1] - Following its inclusion in the Hong Kong Stock Connect, northbound capital has continuously increased its holdings in药捷安康, with investments of 180 million HKD and 142 million HKD on September 12 and September 15, respectively [1] Group 2: Company Overview -药捷安康 focuses on the discovery and development of small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidate products and multiple preclinical-stage candidates in its pipeline [1] Group 3: Financial Performance - The company reported no revenue from its main business in the first half of the year, with other income and gains declining from 10.4 million HKD in the first half of 2024 to 3.6 million HKD, a decrease of 65.1% [1] - The core product,替恩戈替尼 (TT-00420), has recently received multiple favorable developments [1]

Core Viewpoint - The stock of药捷安康-B (02617) has surged over 60% in early trading, reaching a high of 679.5 HKD, with a cumulative increase of nearly 10 times since its entry into the market [1] Group 1: Stock Performance - As of the latest update, the stock is up 50.6%, trading at 625.5 HKD, with a transaction volume of 1.177 billion HKD and a market capitalization that briefly surpassed 250 billion HKD [1] - Following its inclusion in the Hong Kong Stock Connect program effective September 8, there has been a continuous increase in investment from northbound funds, with purchases of 180 million HKD and 142 million HKD on September 12 and September 15, respectively [1] Group 2: Company Overview -药捷安康 focuses on the discovery and development of small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidate products and multiple preclinical-stage candidates in its pipeline [1] Group 3: Financial Performance - The company reported no revenue from its main business in the first half of the year, with other income declining from 10.4 million HKD in the first half of 2024 to 3.6 million HKD, a decrease of 65.1% [1] - The core product,替恩戈替尼 (TT-00420), has recently received multiple favorable developments [1]